These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36551262)

  • 1. Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer.
    Liu Z; Gao J; Gu R; Shi Y; Hu H; Liu J; Huang J; Zhong C; Zhou W; Yang Y; Gong C
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-platform meta-analysis of multiple gene expression profiles identifies novel expression signatures in acquired anthracycline-resistant breast cancer.
    Lee YS; Ryu SW; Bae SJ; Park TH; Kwon K; Noh YH; Kim SY
    Oncol Rep; 2015 Apr; 33(4):1985-93. PubMed ID: 25695524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
    Ravdin PM
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
    Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
    Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
    Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
    Braunstein M; Liao L; Lyttle N; Lobo N; Taylor KJ; Krzyzanowski PM; Kalatskaya I; Yao CQ; Stein LD; Boutros PC; Twelves CJ; Marcellus R; Bartlett JM; Spears M
    Breast Cancer Res; 2016 Feb; 18(1):16. PubMed ID: 26852132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
    Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Østenstad B; Lundgren S; Berge EO; Risberg T; Mjaaland I; Maehle L; Engebretsen LF; Lillehaug JR; Lønning PE
    PLoS One; 2008 Aug; 3(8):e3062. PubMed ID: 18725978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
    Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.
    Zheng L; Li X; Meng X; Chou J; Hu J; Zhang F; Zhang Z; Xing Y; Liu Y; Xi T
    Mol Cell Endocrinol; 2016 May; 427():133-42. PubMed ID: 26980484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
    Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
    Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.
    Wiegmans AP; Saunus JM; Ham S; Lobb R; Kutasovic JR; Dalley AJ; Miranda M; Atkinson C; Foliaki ST; Ferguson K; Niland C; Johnstone CN; Lewis V; Collins SJ; Lakhani SR; Al-Ejeh F; Möller A
    JCI Insight; 2019 Feb; 5(6):. PubMed ID: 30830863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of p53 Codon72 SNP in breast cancer risk and anthracycline resistance.
    Arfaoui A; Douik H; Kablouti G; Chaaben AB; Handiri N; Zid Z; Ouni N; Zouiouch F; Ayari F; Mamoughli T; Bouassida J; Abazza H; Harzallaha L; Guemira F
    Anticancer Res; 2015 Mar; 35(3):1763-9. PubMed ID: 25750340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthracycline resistance in breast cancer: clinical applications of current knowledge.
    Ravdin PM
    Eur J Cancer; 1995; 31A Suppl 7():S11-4. PubMed ID: 8562184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
    Chewchuk S; Guo B; Parissenti AM
    PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogene associated cDNA microarray analysis shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lymphoma.
    Kawano R; Karube K; Kikuchi M; Takeshita M; Tamura K; Uike N; Eto T; Ohshima K; Suzumiya J
    J Clin Exp Hematop; 2009 May; 49(1):1-7. PubMed ID: 19474511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients.
    Wang Z; Chen J; Zhong MZ; Huang J; Hu YP; Feng DY; Zhou ZJ; Luo X; Liu ZQ; Jiang WZ; Zhou WB
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):535-543. PubMed ID: 28243684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of eIF3a on anthracycline-based chemotherapy resistance by regulating DSB DNA repair.
    Chen J; Liu JY; Dong ZZ; Zou T; Wang Z; Shen Y; Zhuo W; Li XP; Xiao D; Liu HT; Chen X; Zhou HH; Liu ZQ; Zhang JT; Yin JY
    Biochem Pharmacol; 2021 Aug; 190():114616. PubMed ID: 34022189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current options in treatment of anthracycline-resistant breast cancer.
    Kröger N; Achterrath W; Hegewisch-Becker S; Mross K; Zander AR
    Cancer Treat Rev; 1999 Oct; 25(5):279-91. PubMed ID: 10544072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
    Lehmann-Che J; André F; Desmedt C; Mazouni C; Giacchetti S; Turpin E; Espié M; Plassa LF; Marty M; Bertheau P; Sotiriou C; Piccart M; Symmans WF; Pusztai L; de Thé H
    Oncologist; 2010; 15(3):246-52. PubMed ID: 20228131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials.
    Spears M; Yousif F; Lyttle N; Boutros PC; Munro AF; Twelves C; Pritchard KI; Levine MN; Shepherd L; Bartlett JM
    Oncotarget; 2015 Oct; 6(31):31693-701. PubMed ID: 26372731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.